Submission of Earning Call Transcript under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
BALAMINES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Balaji Amines reported strong Q4 FY26 results with revenue of INR403 crores (up 12% YoY) and significantly improved EBITDA margins at 25% versus 19% in Q4 FY25. PAT grew 63% YoY to INR65 crores. For FY26, consolidated revenue stood at INR1,454 crores with EBITDA margin improving to 20%. The company guided for 20-30% volume growth in FY27 with sustainable EBITDA margins of 22-23%. Three new projects—DME, NMM, and ACN—are expected to commission in FY27, while the INR750 crore expansion at subsidiary Balaji Specialty Chemicals is progressing with brownfield products expected H1 FY27 and greenfield products in Q4 FY27. Management maintained its INR3,000 crores revenue target for FY28. The company remains zero-debt at standalone level with consolidated debt of INR133 crores for expansion activities.
The margin improvement from 19% to 25% demonstrates operational efficiency gains and successful cost management. The guided 22-23% EBITDA margin for FY27 provides visibility on profitability sustainability. The aggressive INR3,000 crore revenue target by FY28 backed by INR750 crore capex signals strong growth intent, though near-term volumes will grow modestly at 10-15% in FY27 as new products ramp up.